Alex Matter
Impact in
- Hematology top 5%
- Chronic Myeloid Leukemia Treatments
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
Papers in
- Oncology 9
- Cancer Treatment and Pharmacology 4
- Cancer Cells and Metastasis 2
- Co-authors
- Elisabeth Buchdunger (2 shared papers)Renaud Capdeville (1 shared paper)Urs Regenass (4 shared papers)Klaus Schieweck (2 shared papers)A.S. Bhatnagar (1 shared paper)Brian Druker (1 shared paper)Max M. Burger (2 shared papers)T. Tao (2 shared papers)
- Journals
- International Journal of Cancer (3 papers)Cellular Immunology (2 papers)Cell and Tissue Research (2 papers)Drug Discovery Today (2 papers)Biochemical and Biophysical Research Communications (1 paper)
- Partner nations
- SwitzerlandSingaporeUnited States
In The Last Decade
Alex Matter
36 papers receiving 2.1k citations
Alex Matter's Hit Papers
Peers
Comparison fields: 5 of 124
- Hematology 331
- Genetics 173
- Oncology 421
- Molecular Biology 978
- Cancer Research 196
Countries citing papers authored by Alex Matter
This map shows the geographic impact of Alex Matter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Matter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Matter more than expected).
Fields of papers citing papers by Alex Matter
This network shows the impact of papers produced by Alex Matter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Matter. The network helps show where Alex Matter may publish in the future.
Co-authors
The 25 scholars most cited alongside Alex Matter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Hit paper breakdown → | 2002 | 1166 |
| 2 | 2020 | 106 | |
| 3 | 2001 | 97 | |
| 4 | CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo. | 1988 | 88 |
| 5 | 1979 | 80 | |
| 6 | 2001 | 76 | |
| 7 | 1987 | 70 | |
| 8 | 2014 | 63 | |
| 9 | 1973 | 57 | |
| 10 | 1990 | 55 | |
| 11 | New S-adenosylmethionine decarboxylase inhibitors with potent antitumor activity. | 1992 | 53 |
| 12 | 2009 | 49 | |
| 13 | 2019 | 38 | |
| 14 | 2017 | 29 | |
| 15 | 1971 | 29 | |
| 16 | 2013 | 24 | |
| 17 | Antiproliferative action of a novel fluorinated uridine analog, 5'-deoxy-5-fluorouridine, measured in vitro and in vivo on four different murine tumor lines. | 1982 | 17 |
| 18 | 1974 | 16 | |
| 19 | 1975 | 15 | |
| 20 | 1983 | 14 |
About Alex Matter
Alex Matter is a scholar working on Molecular Biology, Oncology, Immunology, Epidemiology and Cell Biology, having authored 36 papers that have together received 2.2k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (4 papers), Cancer Treatment and Pharmacology (4 papers), Cancer Genomics and Diagnostics (3 papers), melanin and skin pigmentation (2 papers), Cancer Cells and Metastasis (2 papers), Chronic Myeloid Leukemia Treatments (2 papers), T-cell and B-cell Immunology (2 papers) and Influenza Virus Research Studies (2 papers). The work is most often cited by research in Hematology (331 citations), Genetics (173 citations), Oncology (421 citations), Molecular Biology (978 citations) and Cancer Research (196 citations). Alex Matter has collaborated with scholars based in Switzerland, Singapore and United States. Frequent co-authors include Elisabeth Buchdunger, Renaud Capdeville, Urs Regenass, Klaus Schieweck, A.S. Bhatnagar, Brian Druker, Max M. Burger, T. Tao, Enrico Curschellas and Kurt W. Vogel. Their work appears in journals such as International Journal of Cancer, Cellular Immunology, Cell and Tissue Research, Drug Discovery Today and Biochemical and Biophysical Research Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.